Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23562009 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Biological: BIIB019 (Daclizumab High Yield Process);   Drug: Placebo

Indicates status has not been verified in more than two years